Fernanda Costa Svedman

542 total citations
17 papers, 286 citations indexed

About

Fernanda Costa Svedman is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Fernanda Costa Svedman has authored 17 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Fernanda Costa Svedman's work include Cancer Immunotherapy and Biomarkers (10 papers), Melanoma and MAPK Pathways (8 papers) and CAR-T cell therapy research (7 papers). Fernanda Costa Svedman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Melanoma and MAPK Pathways (8 papers) and CAR-T cell therapy research (7 papers). Fernanda Costa Svedman collaborates with scholars based in Sweden, United Kingdom and Australia. Fernanda Costa Svedman's co-authors include Johan Hansson, Demetris Pillas, Veronica Höiom, Suzanne Egyházi Brage, Rainer Tuominen, Søren Brage, Hanna Eriksson, Aliki Taylor, Warangkana Lohcharoenkal and Matteo Bottai and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Fernanda Costa Svedman

14 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernanda Costa Svedman Sweden 9 160 157 67 66 25 17 286
Ewelina Dratkiewicz Poland 12 177 1.1× 235 1.5× 75 1.1× 107 1.6× 27 1.1× 13 403
Janice M. Mehnert United States 8 183 1.1× 303 1.9× 58 0.9× 52 0.8× 12 0.5× 24 409
Puay Hoon Tan Singapore 10 213 1.3× 135 0.9× 98 1.5× 144 2.2× 15 0.6× 17 387
Subrata Manna United States 8 124 0.8× 179 1.1× 106 1.6× 78 1.2× 7 0.3× 12 358
Camilla Avivi Israel 5 218 1.4× 242 1.5× 138 2.1× 68 1.0× 11 0.4× 6 409
Mano Nakamura United Kingdom 6 99 0.6× 115 0.7× 31 0.5× 118 1.8× 18 0.7× 7 266
Emily J. Rowling United Kingdom 8 238 1.5× 293 1.9× 67 1.0× 76 1.2× 26 1.0× 8 429
Loren Lasko United States 11 196 1.2× 288 1.8× 25 0.4× 67 1.0× 5 0.2× 13 421
Kaori Sakaizawa Japan 7 268 1.7× 206 1.3× 133 2.0× 47 0.7× 20 0.8× 11 349
Wieke Zuidervaart Netherlands 7 127 0.8× 270 1.7× 30 0.4× 75 1.1× 7 0.3× 8 402

Countries citing papers authored by Fernanda Costa Svedman

Since Specialization
Citations

This map shows the geographic impact of Fernanda Costa Svedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernanda Costa Svedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernanda Costa Svedman more than expected).

Fields of papers citing papers by Fernanda Costa Svedman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernanda Costa Svedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernanda Costa Svedman. The network helps show where Fernanda Costa Svedman may publish in the future.

Co-authorship network of co-authors of Fernanda Costa Svedman

This figure shows the co-authorship network connecting the top 25 collaborators of Fernanda Costa Svedman. A scholar is included among the top collaborators of Fernanda Costa Svedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernanda Costa Svedman. Fernanda Costa Svedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Svedman, Fernanda Costa, et al.. (2025). Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab. Urologic Oncology Seminars and Original Investigations. 43(8). 467.e21–467.e29.
2.
3.
4.
Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2024). Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.. Journal of Clinical Oncology. 42(16_suppl). 9559–9559. 1 indexed citations
5.
Verbiené, Ingrida, Anna Laurell, Karin Söderkvist, et al.. (2023). Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era. Clinical Genitourinary Cancer. 21(6). e438–e448. 1 indexed citations
6.
Svedman, Fernanda Costa, Veronica Höiom, Vitali Grozman, et al.. (2022). Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. Cancers. 14(3). 702–702. 4 indexed citations
7.
8.
Karlsson, Max, Fernanda Costa Svedman, Abdellah Tebani, et al.. (2021). Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy. Cancer Research. 81(9). 2545–2555. 26 indexed citations
9.
Arance, Ana, Luis de la Cruz‐Merino, Teresa M. Petrella, et al.. (2021). Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology. 39(15_suppl). 9504–9504. 17 indexed citations
10.
Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2020). LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Annals of Oncology. 31. S1173–S1173. 19 indexed citations
11.
Das, Ishani, Margareta Wilhelm, Veronica Höiom, et al.. (2019). Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. Cell Death and Disease. 10(9). 663–663. 20 indexed citations
12.
Svedman, Fernanda Costa, Ishani Das, Rainer Tuominen, et al.. (2019). Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma. Annals of Oncology. 30. v559–v559. 1 indexed citations
13.
Svedman, Fernanda Costa, Warangkana Lohcharoenkal, Matteo Bottai, et al.. (2018). Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma. PLoS ONE. 13(11). e0206942–e0206942. 35 indexed citations
14.
Azimi, Alireza, Rainer Tuominen, Fernanda Costa Svedman, et al.. (2017). Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Cell Death and Disease. 8(8). e3029–e3029. 30 indexed citations
15.
Svedman, Fernanda Costa, et al.. (2016). Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature. Clinical Epidemiology. 8. 109–109. 79 indexed citations
16.
Svedman, Fernanda Costa, et al.. (2016). Surgical outcomes in patients with cutaneous malignant melanoma in Europe – a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 31(4). 603–615. 22 indexed citations
17.
Svedman, Fernanda Costa, et al.. (2009). Prostasin, A Potential Tumor Marker in Ovarian Cancer- A Pilot Study. Clinics. 64(7). 641–644. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ewelina Dratkiewicz Breakdown of academic impact, for papers by Janice M. Mehnert Breakdown of academic impact, for papers by Puay Hoon Tan Breakdown of academic impact, for papers by Subrata Manna Breakdown of academic impact, for papers by Camilla Avivi Breakdown of academic impact, for papers by Mano Nakamura Breakdown of academic impact, for papers by Emily J. Rowling Breakdown of academic impact, for papers by Loren Lasko Breakdown of academic impact, for papers by Kaori Sakaizawa Breakdown of academic impact, for papers by Wieke Zuidervaart
Rankless by CCL
2026